InMed Pharmaceuticals
Clinical-stage pharmaceutical company developing small-molecule therapeutics that target CB1/CB2 receptor pathways and a parallel cannabinoid synthesis manufacturing capability to produce bioidentical, pharmaceutical-grade rare cannabinoids. Operates preclinical and clinical programs across neurological, ophthalmic and dermatological indications and supplies high-purity rare cannabinoids for B2B customers via a manufacturing subsidiary.
Industries
Nr. of Employees
small (1-50)
InMed Pharmaceuticals
Products
Pipeline of small-molecule therapeutics targeting CB1/CB2 pathways
Clinical- and preclinical-stage small-molecule programs focused on neurological (including Alzheimer’s disease), ophthalmic (dry age-related macular degeneration) and dermatological (epidermolysis bullosa, glaucoma) indications.
Synthetic cannabinoid manufacturing system (IntegraSyn-style platform)
A platform-level manufacturing approach designed to produce bioidentical cannabinoids at pharmaceutical grade and scale as an alternative to plant extraction.
Pipeline of small-molecule therapeutics targeting CB1/CB2 pathways
Clinical- and preclinical-stage small-molecule programs focused on neurological (including Alzheimer’s disease), ophthalmic (dry age-related macular degeneration) and dermatological (epidermolysis bullosa, glaucoma) indications.
Synthetic cannabinoid manufacturing system (IntegraSyn-style platform)
A platform-level manufacturing approach designed to produce bioidentical cannabinoids at pharmaceutical grade and scale as an alternative to plant extraction.
Services
Manufacture and supply of high-purity bioidentical rare cannabinoids (B2B)
Production and commercial sale of pharmaceutical-grade, THC-free rare cannabinoids for use as raw ingredients in health and therapeutic products.
Manufacture and supply of high-purity bioidentical rare cannabinoids (B2B)
Production and commercial sale of pharmaceutical-grade, THC-free rare cannabinoids for use as raw ingredients in health and therapeutic products.
Expertise Areas
- Clinical trial management and execution
- Cannabinoid synthesis and manufacturing
- Preclinical pharmacology for neurodegenerative and ophthalmic diseases
- Dermatological formulation development
Key Technologies
- CB1/CB2-targeted small-molecule therapeutics
- Synthetic cannabinoid manufacturing platform
- Microbial metabolic engineering
- Enzyme-based biosynthetic pathways